The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and (131)I-metaiodobenzylguanidine-scintigraphy. The role of (111)-indium-diethylenetriaminepentaacetic acid [(111)In-DTPA(0)] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [(111)In-DTPA(0)] octreotide scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by (90)Y-1,4,7,10-Tetraazacyclododecane-N, N',N '',N '''tetralacetic acid (DOTA(0))-Tyr(3)-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [(111)In-DTPA(0)] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes.

Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease / Pulcrano, M; Camera, Luigi; Pagano, L; DEL VECCHIO, Silvana; Ferone, D; Bodei, L; Murgia, A; Pace, L; Storto, G; Paganelli, G; Colao, Annamaria; Salvatore, Marco; Lombardi, Gaetano; Biondi, Bernadette. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - STAMPA. - 31:4(2008), pp. 352.-359.

Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.

CAMERA, LUIGI;DEL VECCHIO, SILVANA;COLAO, ANNAMARIA;SALVATORE, MARCO;LOMBARDI, GAETANO;BIONDI, BERNADETTE
2008

Abstract

The identification of patients with von Hippel-Lindau (VHL) disease dictates accurate genetic counseling of family members, whereas screening for early detection of visceral and neurological involvement is usually performed by a combination of radiological and nuclear medicine techniques such as ultrasonography or contrast-enhanced computed tomography of the upper abdomen, magnetic resonance imaging of the central nervous system and (131)I-metaiodobenzylguanidine-scintigraphy. The role of (111)-indium-diethylenetriaminepentaacetic acid [(111)In-DTPA(0)] octreotide scintigraphy in this clinical context has never been investigated. Here, we report imaging findings in a VHL patient and in 3 consecutive family members undergoing clinical and radiological screening that included [(111)In-DTPA(0)] octreotide scintigraphy in addition to the above-mentioned procedures. Somatostatin receptor expression was investigated in vitro by immunohistochemistry in pancreatic tumor sections. On the basis of in vivo and in vitro findings, octreotide long-acting release treatment followed by (90)Y-1,4,7,10-Tetraazacyclododecane-N, N',N '',N '''tetralacetic acid (DOTA(0))-Tyr(3)-octreotide led to a lack of progression in this patient although this result is a possibility which needs to be proved by further investigation and longer follow-up. The results of this study suggest that [(111)In-DTPA(0)] octreotide scintigraphy may be helpful in the routine work-up of VHL patients for diagnostic and therapeutic purposes.
2008
Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease / Pulcrano, M; Camera, Luigi; Pagano, L; DEL VECCHIO, Silvana; Ferone, D; Bodei, L; Murgia, A; Pace, L; Storto, G; Paganelli, G; Colao, Annamaria; Salvatore, Marco; Lombardi, Gaetano; Biondi, Bernadette. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 0391-4097. - STAMPA. - 31:4(2008), pp. 352.-359.
File in questo prodotto:
File Dimensione Formato  
The identification of patients with von Hippel.docx

solo utenti autorizzati

Tipologia: Abstract
Licenza: Dominio pubblico
Dimensione 14.12 kB
Formato Microsoft Word XML
14.12 kB Microsoft Word XML   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/335778
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact